Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kabiven is a sterile, hypertonic emulsion for intravenous infusion, provided in a specialized three-chamber bag system designed for parenteral nutrition (PN). Developed by Fresenius Kabi, it is indicated as a source of calories, protein (amino acids), electrolytes, and essential fatty acids for adult patients when oral or enteral nutrition is impossible, insufficient, or contraindicated. The three-chamber bag allows for the separate storage of an amino acid solution with electrolytes, a dextrose solution, and a lipid emulsion (specifically Intralipid, a soybean oil-based emulsion), which are mixed just prior to administration. This formulation helps prevent essential fatty acid deficiency and treats negative nitrogen balance. While primarily used in adults, clinical investigations have explored its safety and efficacy in pediatric populations aged 2 to 16 years.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kabiven.